Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Hermans

Showing results (21-30 of 122) with videos related to

Pageof 13
Sort By:
Haematologica|October 16, 2012
Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapyRobert Weinkove, Collin R Brooks, John M Carter, et al.
Journal of Immunological Methods|August 6, 2013
Efficient depletion of chronic lymphocytic leukemia B cells using serial rounds of immunomagnetic depletionRobert Weinkove, Collin R Brooks, John M Carter, et al.
Immunology and Cell Biology|July 13, 2006
5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapyKate E Matthews, Ian F Hermans, Joanna M Roberts, et al.
BMC Pulmonary Medicine|December 6, 2017
Effects of treatment changes on asthma phenotype prevalence and airway neutrophil functionCollin R Brooks, Christine J Van Dalen, Elizabeth Harding, et al.
Journal of Immunological Methods|February 22, 2014
Sustained in vivo depletion of splenic langerin(+) CD8α(+) dendritic cells is well-tolerated by lang-DTREGFP miceKelly A Prendergast, Taryn L Osmond, Sotaro Ochiai, et al.
The Journal of Experimental Medicine|April 6, 1999
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell helpK D McCoy, I F Hermans, J H Fraser, et al.
Cancer Research|December 18, 2003
Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma modelIan F Hermans, Tsung Wen Chong, Michael J Palmowski, et al.
Cells|April 30, 2021
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer ImmunotherapyZhe Fu, Alexandra M Mowday, Jeff B Smaill, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 2, 2015
Splenic Dendritic Cells Involved in Cross-Tolerance of Tumor Antigens Can Play a Stimulatory Role in Adoptive T-Cell TherapyJohn D Gibbins, Lindsay R Ancelet, Taryn L Osmond, et al.
Frontiers in Immunology|June 6, 2018
Langerin<sup>+</sup> CD8α<sup>+</sup> Dendritic Cells Drive Early CD8<sup>+</sup> T Cell Activation and IL-12 Production During Systemic Bacterial InfectionKelly A Prendergast, Naomi J Daniels, Troels R Petersen, et al.
Pageof 13

Showing results (21-30 of 122) with videos related to

Sort By:
Pageof 13
Haematologica|October 16, 2012
Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapyRobert Weinkove, Collin R Brooks, John M Carter, et al.
Journal of Immunological Methods|August 6, 2013
Efficient depletion of chronic lymphocytic leukemia B cells using serial rounds of immunomagnetic depletionRobert Weinkove, Collin R Brooks, John M Carter, et al.
Immunology and Cell Biology|July 13, 2006
5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapyKate E Matthews, Ian F Hermans, Joanna M Roberts, et al.
BMC Pulmonary Medicine|December 6, 2017
Effects of treatment changes on asthma phenotype prevalence and airway neutrophil functionCollin R Brooks, Christine J Van Dalen, Elizabeth Harding, et al.
Journal of Immunological Methods|February 22, 2014
Sustained in vivo depletion of splenic langerin(+) CD8α(+) dendritic cells is well-tolerated by lang-DTREGFP miceKelly A Prendergast, Taryn L Osmond, Sotaro Ochiai, et al.
The Journal of Experimental Medicine|April 6, 1999
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell helpK D McCoy, I F Hermans, J H Fraser, et al.
Cancer Research|December 18, 2003
Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma modelIan F Hermans, Tsung Wen Chong, Michael J Palmowski, et al.
Cells|April 30, 2021
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer ImmunotherapyZhe Fu, Alexandra M Mowday, Jeff B Smaill, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 2, 2015
Splenic Dendritic Cells Involved in Cross-Tolerance of Tumor Antigens Can Play a Stimulatory Role in Adoptive T-Cell TherapyJohn D Gibbins, Lindsay R Ancelet, Taryn L Osmond, et al.
Frontiers in Immunology|June 6, 2018
Langerin<sup>+</sup> CD8α<sup>+</sup> Dendritic Cells Drive Early CD8<sup>+</sup> T Cell Activation and IL-12 Production During Systemic Bacterial InfectionKelly A Prendergast, Naomi J Daniels, Troels R Petersen, et al.
Pageof 13